Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients

Objective: To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting. Methods: The study is prospective and observational based on real-world evidence, performed by different medical...

ver descrição completa

Detalhes bibliográficos
Autores: Córdoba Sánchez, Julián, Picola, Natàlia, Rodriguez-Vida, Alejo, Costa, Marc, Marmolejo Castañeda, David, Pérez Márquez, Meritxell, Muñoz-Rodríguez, Jesús, Gaya Sopena, Josep Maria, Bravo, Alejandra, Buisan, Oscar, Servian, Pol, Suárez Novo, José Francisco, Musquera Felip, Mireia, Ribal, María José, Alcaraz Asensio, Antonio, Vilaseca, Antoni
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/61339
Acesso em linha:http://hdl.handle.net/10230/61339
http://dx.doi.org/10.1002/cam4.6769
Access Level:acceso abierto
Palavra-chave:Apalutamide
High-risk non-metastatic castration-resistant prostate cancer
Metastatic hormone-sensitive prostate cancer
Prostate cancer
Real-world
id ES_3b317bb1bdcaee7b1b6040c4c67a1deb
oai_identifier_str oai:recercat.cat:10230/61339
network_acronym_str ES
network_name_str España
repository_id_str
spelling Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patientsCórdoba Sánchez, JuliánPicola, NatàliaRodriguez-Vida, AlejoCosta, MarcMarmolejo Castañeda, DavidPérez Márquez, MeritxellMuñoz-Rodríguez, JesúsGaya Sopena, Josep MariaBravo, AlejandraBuisan, OscarServian, PolSuárez Novo, José FranciscoMusquera Felip, MireiaRibal, María JoséAlcaraz Asensio, AntonioVilaseca, AntoniApalutamideHigh-risk non-metastatic castration-resistant prostate cancerMetastatic hormone-sensitive prostate cancerProstate cancerReal-worldObjective: To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting. Methods: The study is prospective and observational based on real-world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022. Results: Of 227 patients treated with apalutamide, 10% had ECOG-PS 2, and 41% were diagnosed with new-generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synchronous metastases, and 22% were M1a. In the nmCRPC (18 patients), 82 years was the median age, and 81% ≤6 months had PSA doubling time. Patients achieved PSA90 in 92% of mHSPC and 50% of nmCRPC and PSA ≤0.2 in 71% of mHSPC and 39% of nmCRPC. Treatment-related adverse events occurred in 40.1% of mHSPC and 44.4% of nmCRPC. After discontinuation of apalutamide due to disease progression, 54.5% in mHSPC and 75% in nmCRPC started chemotherapy, while after discontinuation because of adverse events, 73.3% in mHSPC and 100% in nmCRPC continued with other hormonal-therapies. Conclusions: The efficacy and safety of apalutamide were similar to that described in the pivotal trials, despite including an older and more comorbid population. Usually, subsequent therapies after apalutamide differed depending on the reason for discontinuation: by disease progression started chemotherapy and by adverse events hormonal sequencing.Wiley202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/61339http://dx.doi.org/10.1002/cam4.6769reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCancer Med. 2023 Dec;12(24):21969-77© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/613392026-05-29T05:05:01Z
dc.title.none.fl_str_mv Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
title Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
spellingShingle Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
Córdoba Sánchez, Julián
Apalutamide
High-risk non-metastatic castration-resistant prostate cancer
Metastatic hormone-sensitive prostate cancer
Prostate cancer
Real-world
title_short Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
title_full Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
title_fullStr Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
title_full_unstemmed Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
title_sort Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
dc.creator.none.fl_str_mv Córdoba Sánchez, Julián
Picola, Natàlia
Rodriguez-Vida, Alejo
Costa, Marc
Marmolejo Castañeda, David
Pérez Márquez, Meritxell
Muñoz-Rodríguez, Jesús
Gaya Sopena, Josep Maria
Bravo, Alejandra
Buisan, Oscar
Servian, Pol
Suárez Novo, José Francisco
Musquera Felip, Mireia
Ribal, María José
Alcaraz Asensio, Antonio
Vilaseca, Antoni
author Córdoba Sánchez, Julián
author_facet Córdoba Sánchez, Julián
Picola, Natàlia
Rodriguez-Vida, Alejo
Costa, Marc
Marmolejo Castañeda, David
Pérez Márquez, Meritxell
Muñoz-Rodríguez, Jesús
Gaya Sopena, Josep Maria
Bravo, Alejandra
Buisan, Oscar
Servian, Pol
Suárez Novo, José Francisco
Musquera Felip, Mireia
Ribal, María José
Alcaraz Asensio, Antonio
Vilaseca, Antoni
author_role author
author2 Picola, Natàlia
Rodriguez-Vida, Alejo
Costa, Marc
Marmolejo Castañeda, David
Pérez Márquez, Meritxell
Muñoz-Rodríguez, Jesús
Gaya Sopena, Josep Maria
Bravo, Alejandra
Buisan, Oscar
Servian, Pol
Suárez Novo, José Francisco
Musquera Felip, Mireia
Ribal, María José
Alcaraz Asensio, Antonio
Vilaseca, Antoni
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Apalutamide
High-risk non-metastatic castration-resistant prostate cancer
Metastatic hormone-sensitive prostate cancer
Prostate cancer
Real-world
topic Apalutamide
High-risk non-metastatic castration-resistant prostate cancer
Metastatic hormone-sensitive prostate cancer
Prostate cancer
Real-world
description Objective: To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting. Methods: The study is prospective and observational based on real-world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022. Results: Of 227 patients treated with apalutamide, 10% had ECOG-PS 2, and 41% were diagnosed with new-generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synchronous metastases, and 22% were M1a. In the nmCRPC (18 patients), 82 years was the median age, and 81% ≤6 months had PSA doubling time. Patients achieved PSA90 in 92% of mHSPC and 50% of nmCRPC and PSA ≤0.2 in 71% of mHSPC and 39% of nmCRPC. Treatment-related adverse events occurred in 40.1% of mHSPC and 44.4% of nmCRPC. After discontinuation of apalutamide due to disease progression, 54.5% in mHSPC and 75% in nmCRPC started chemotherapy, while after discontinuation because of adverse events, 73.3% in mHSPC and 100% in nmCRPC continued with other hormonal-therapies. Conclusions: The efficacy and safety of apalutamide were similar to that described in the pivotal trials, despite including an older and more comorbid population. Usually, subsequent therapies after apalutamide differed depending on the reason for discontinuation: by disease progression started chemotherapy and by adverse events hormonal sequencing.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/61339
http://dx.doi.org/10.1002/cam4.6769
url http://hdl.handle.net/10230/61339
http://dx.doi.org/10.1002/cam4.6769
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancer Med. 2023 Dec;12(24):21969-77
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406290698043392
score 15,81155

Registos relacionados